Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap

Aldeyra Therapeutics, Inc. , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it has entered into...

Related Keywords

United States ,Goodwin Proctor ,Drug Administration ,Aldeyra Therapeutics Inc ,Drug Administration New Application ,Exchange Commission ,Securities Exchange ,Nasdaq ,Abbvie Inc ,Aldeyra Therapeutics ,Current Report ,Aquilo Partners ,Drug Administration New Application Review ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Report ,Markets ,